Enliven Therapeutics, Inc. (ELVN) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $33.97: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 4.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Below-average business quality; Negative price momentum.
Enliven Therapeutics is a clinical-stage biopharmaceutical company developing ELVN-001, a highly selective BCR-ABL tyrosine kinase inhibitor in Phase 1 ENABLE trial for chronic myeloid leukemia (CML), with Phase 3 ENABLE-2 planned for 2H 2026. The company has no approved... Read more
Sell if holding. Engine safety override at $33.97: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 4.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Score 5.4/10, moderate confidence.
Passes 6/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 65d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent developments
updated 2026-06-09Recent Developments — Enliven Therapeutics, Inc.
Latest news
- NEWS Reported Earlier, Enliven Therapeutics Prices Upsized Public Offering Of 8,933,334 Common Shares At $37.50, Pre-Funded W — benzinga Jun 12, 2026 positive
- NEWS Crude Oil Edges Higher; Driven Brands Posts Upbeat Earnings — benzinga Jun 11, 2026 neutral
- NEWS Stitch Fix, Intel, KLA And Other Big Stocks Moving Higher On Thursday — benzinga Jun 11, 2026 positive
- NEWS Enliven Therapeutics Presents Data From The Phase 1 Enable Clinical Trial Evaluating ELVN-001 In Patients With Previousl — benzinga Jun 11, 2026 positive
- NEWS This Grand Canyon Education Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday — benzinga Jun 9, 2026 neutral
Generated 2026-06-12T18:41:35Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelineELVN-00110-K Item 1A: 'We are substantially dependent on ELVN-001. If we are unable to advance ELVN-001 through clinical development, obtain regulatory approval and ultimately commercialize or license ELVN-001...our business will be materially harmed.'
- HIGHSupplierPharmaron10-K Item 1: 'we have obtained the custom-manufactured starting materials for active pharmaceutical ingredients ("APIs") manufacture from Pharmaron and Hande Sciences and our good manufacturing practice ("GMP") APIs from Pharmaron.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
2 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $33.97: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.4/10 and A.R:R 4.5:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 13%; Below-average business quality; Negative price momentum. Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $32.45. Score 5.4/10, moderate confidence.
Take-profit target: $51.44 (+53.0% upside). Prior stop was $32.45. Stop-loss: $32.45.
Concentration risk — Pipeline: ELVN-001; Concentration risk — Supplier: Pharmaron; Quality below floor (1.6 < 4.0).
Enliven Therapeutics, Inc. trades at a P/E of N/A (forward -14.5). TrendMatrix value score: 9.0/10. Verdict: Sell.
17 analysts cover ELVN with a consensus score of 4.3/5. Average price target: $59.
What does Enliven Therapeutics, Inc. do?Enliven Therapeutics is a clinical-stage biopharmaceutical company developing ELVN-001, a highly selective BCR-ABL...
Enliven Therapeutics is a clinical-stage biopharmaceutical company developing ELVN-001, a highly selective BCR-ABL tyrosine kinase inhibitor in Phase 1 ENABLE trial for chronic myeloid leukemia (CML), with Phase 3 ENABLE-2 planned for 2H 2026. The company has no approved products or revenue and is substantially dependent on ELVN-001 for all future commercial value.